Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-SLAMF7 CAR T-cells in Multiple Myeloma
NCT03958656Phase 1Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2019
- Primary completion
- Oct 2020
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of anti-SLAMF7 CAR T cells in multiple myeloma (MM) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Number of Participants That Had Any Grade <=2, and 3, 4 and 5 Adverse Events up to 6 months. Started Jun 2019; status: completed.
02
Drugs
anti-SLAMF7 CAR T cells
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03958656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03958656.